Nils Ackermann (Dreamstime)

General information

RE-SAMPLE - REal-time data monitoring for Shared, Adaptive, Multi-domain and Personalised prediction and decision making for Long-term Pulmonary care Ecosystems

WHY

In Europe alone, an estimated 4 to 10 per cent of the population suffers from Chronic Obstructive Pulmonary Disease (COPD). It is a progressive lung condition that significantly impacts patients’ quality of life and life expectancy. Patients with COPD often require various treatment approaches to relieve their respiratory (e.g., shortness of breath, coughing) and non-respiratory (e.g., fatigue) symptoms, as well as other accompanying conditions (e.g., diabetes, cardiovascular diseases, mental health issues).

WHAT

Main objectives
  • empower patients with COPD and CCCs in self-care by developing a multidisciplinary, adaptive virtual companionship programme
  • drive structural change in healthcare together with patients, healthcare professionals, scientists, policy makers, and industry

Over the course of four years (2021-2025), RE-SAMPLE will work to transform the healthcare journey of patients with COPD, and to set a standard of care for patients suffering from complex chronic conditions (CCC).

RE-SAMPLE will use real-world data (RWD) to monitor COPD symptoms beyond scheduled medical check-ups. Such information will give doctors, caregivers and patients a unique insight into common, day-to-day triggers that can lead to health complications.

The data and analyses will feed into the development of personalised treatment and a virtual companionship programme.

RE-SAMPLE aims to mitigate the severity of complications and reduce their frequency. Our hope is that RE-SAMPLE’s approach to integrated care will help patients feel safer in-between medical visits, and equally, that patients are involved meaningfully in the management of their care.

HOW

Using Artificial Intelligence, RE-SAMPLE hopes to gain unique insights into the complex relationships between patients’ clinical and non-clinical characteristics, and how these impact disease progression, mental wellbeing, and physical health. The data and analyses will also serve as a basis for predictive models that could help patients and their doctors make treatment and lifestyle changes in time to reduce serious complications.

To ensure that we can gather quality data and that our system truly fits the needs of patients, RE-SAMPLE will rely on inclusive design and a citizen science approach.

Meaningful collaboration with citizens cannot be achieved without trust. One of our project’s hallmarks is the early integration of security and privacy settings across all technical (the system itself will be designed from this perspective) and non-technical (the project will adhere to rigorous ethical and data protection standards) aspects of RE-SAMPLE.

Expected impact
  • Accurate predictions of CCC exacerbations, more exacerbations are prevented or timely treated
  • Earlier initiation of appropriate treatment resulting in less severe CCC exacerbations, accelerated recovery, and reduced healthcare utilisation
  • Privacy-preserving artificial intelligence, previously reserved for research purposes only, in healthcare application
  • A digital transformation of healthcare by equally empowering technology, healthcare provider and patient
  • Incorporation of evidence-based interventions and personalised treatment approaches within clinical guidelines
  • Enhanced care delivery substitution from secondary to home-based support
  • Increased transparency and accountability for cross-border health data exchange

WHO

The RE-SAMPLE project consortium reflects its multidisciplinary approach by bringing together partners specialising in respiratory medicine, artificial intelligence, RWD, privacy, ethics, data protection, and health policy.

Request more information
Contact us
Participate in our research
Sign up
Subscribe to our newsletter
Subscribe